Comparison of the FCSRT and RBANS in screening for early ad clinical trials: Enrichment for disease progression

Free and Cued Selective Reminding Test-Immediate Recall (FCSRT-IR) and the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS-DMI) assess episodic memory and have been used to improve screening procedures to efficiently identify potential participants for treatment trials in prodromal-to-mild AD. The relative utility of the FCSRT-IR versus RBANS-DMI for identifying participants more likely to experience clinical decline and/or exhibit treatment benefits remains uncertain. This presentation compares the rates and variability of clinical progression on cognitive and functional endpoints in prodromal-to-mild AD participants from the CREAD (NCT02670083) and Tauriel (NCT03289143) clinical studies, that included the FCSRT-IR or RBANS-DMI as part of their screening procedures and inclusion criteria.